CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
Abemaciclib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02981342
NCT02981342Phase 2Completed
CompareCT.gov

An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

Eli Lilly and Company·interventional·Posted Dec 5, 2016·Updated Nov 20, 2019

In Brief

A Phase 2 clinical trial evaluating Abemaciclib, LY3023414, and 2 other interventions for Pancreatic Ductal Adenocarcinoma. Completed, enrolled 106 participants across 32 sites in 8 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Ductal Adenocarcinoma
CountriesAustralia, Belgium, France, Israel, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 5, 2016
Enrollment StartJan 12, 2017
Primary CompletionApr 20, 2018
Study CompletionNov 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago

Interventions

Abemaciclibdrug

Administered orally

LY3023414drug

Administered orally

Gemcitabinedrug

Administered IV

Capecitabinedrug

Administered orally